Lepper Philipp M, Schumann Christian, Triantafilou Kathy, Rasche F Maximilian, Schuster Tibor, Frank Hedwig, Schneider E Marion, Triantafilou Martha, von Eynatten Maximilian
Department of Intensive Care Medicine, University Hospital of Bern (Inselspital), Bern, Switzerland.
J Am Coll Cardiol. 2007 Jul 3;50(1):25-31. doi: 10.1016/j.jacc.2007.02.070. Epub 2007 Jun 18.
In this study we tested the hypothesis that lipopolysaccharide-binding protein (LBP) might be able to be used as a biomarker for coronary artery disease (CAD).
The mechanisms by which the innate immune recognition of pathogens could lead to atherosclerosis remain unclear. Lipopolysaccharide-binding protein is the first protein to encounter lipopolysaccharide and to deliver it to its cellular targets, toll-like receptors; therefore, its presence might be a reliable biomarker that indicates activation of innate immune responses.
A total of 247 men undergoing elective coronary angiography were studied, and the extent of coronary atherosclerosis was assessed by 2 established scores: "extent score" and "severity score." Levels of LBP, markers of inflammation, and traditional risk factors for CAD were assessed.
Serum LBP concentration was significantly increased in 172 patients with angiographically confirmed CAD compared with 75 individuals without coronary atherosclerosis (20.6 +/- 8.7 pg/ml vs. 17.1 +/- 6.0 pg/ml, respectively; p = 0.002). Moreover in multivariable logistic regression analyses, adjusted for established cardiovascular risk factors and markers of systemic inflammation, LBP was a significant and independent predictor of prevalent CAD (p < 0.05 in all models).
Lipopolysaccharide-binding protein might serve as a novel marker for CAD in men. The present results underlie the potential importance of innate immune mechanisms for CAD. Further studies are warranted to bolster the data and to identify pathogenetic links between innate immune system activation and atherosclerosis.
在本研究中，我们检验了脂多糖结合蛋白（LBP）可能可作为冠状动脉疾病（CAD）生物标志物的假说。
病原体的固有免疫识别导致动脉粥样硬化的机制仍不清楚。脂多糖结合蛋白是首个接触脂多糖并将其传递至细胞靶点（Toll样受体）的蛋白质；因此，其存在可能是表明固有免疫反应激活的可靠生物标志物。
共研究了247名接受选择性冠状动脉造影的男性，通过两种既定评分“范围评分”和“严重程度评分”评估冠状动脉粥样硬化的程度。评估了LBP水平、炎症标志物和CAD的传统危险因素。
与75名无冠状动脉粥样硬化的个体相比，172名经血管造影证实患有CAD的患者血清LBP浓度显著升高（分别为20.6±8.7 pg/ml和17. ±6.0 pg/ml；p = 0.002）。此外，在多变量逻辑回归分析中，校正既定的心血管危险因素和全身炎症标志物后，LBP是CAD患病率的显著且独立预测因子（所有模型中p < 0.05）。
脂多糖结合蛋白可能是男性CAD的新型标志物。目前的结果突显了固有免疫机制对CAD的潜在重要性。有必要进行进一步研究以加强数据并确定固有免疫系统激活与动脉粥样硬化之间的发病学联系。
